Engflag

Tide Plus

Quick links to important sections

Tide Plus

Tide Plus_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tide Plus

Understanding Tide Plus

Tide Plus is a combination pharmaceutical product formulated to assist in the management of fluid retention and high blood pressure. It belongs to a category of medications known as diuretics, which are commonly referred to as water pills. The formulation typically combines two distinct active ingredients that work through different mechanisms in the kidneys to facilitate the removal of excess salt and water from the body.

Composition and Mechanism

The primary components of Tide Plus work together to regulate fluid balance. One ingredient acts as a loop diuretic, which increases the excretion of sodium and water by affecting a specific part of the kidney called the loop of Henle. The second ingredient is often a potassium-sparing diuretic, included to help maintain stable potassium levels in the blood, as many potent diuretics can otherwise lead to potassium depletion.

Clinical Applications

This medication is primarily utilized for conditions where the body retains too much fluid, a state known as edema. It is frequently prescribed for individuals experiencing:

  • Congestive Heart Failure: To reduce the workload on the heart by decreasing the total volume of fluid circulating in the bloodstream.
  • Hypertension: To lower blood pressure levels, which helps reduce the long-term risk of cardiovascular complications.
  • Hepatic Cirrhosis: To manage fluid accumulation in the abdomen or limbs resulting from liver dysfunction.
  • Renal Impairment: To assist the kidneys in maintaining fluid homeostasis when their natural filtration capacity is compromised.

By reducing the volume of fluid in the blood vessels, Tide Plus helps to ease the pressure on the cardiovascular system and alleviate the physical discomfort and swelling associated with fluid buildup.

What side effects are possible with Tide Plus?

Possible Side Effects and Safety Information

The following section details the officially documented adverse effects and safety constraints of Tide Plus (Spironolactone and Torasemide) as published in government regulatory documents.

Official Adverse Reactions and Frequencies

Adverse reactions are classified by frequency and categorized by the organ systems they affect. The primary safety focus involves electrolyte balance due to the combination of the potassium-sparing (Spironolactone) and loop (Torasemide) diuretics.

Classification Example Side Effects (Regulatory Basis)
Very Common Hyperkalemia (elevated potassium levels).
Common Gynecomastia (breast enlargement in males), dizziness, nausea, muscle spasms, rash.
Uncommon Menstrual disorders, female breast pain.

Serious Adverse Reactions and Safety Constraints

Regulatory information documents serious adverse reactions and conditions that prohibit the use of Tide Plus. These are considered clinically significant and include risks beyond the common side effect profiles:

  • Serious Adverse Reactions: Documented risks include Severe Hyperkalemia, which can affect cardiac rhythm; Acute Kidney Injury; and severe cutaneous reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

  • Population and Usage Constraints: The medication is contraindicated in patients with pre-existing conditions such as Severe Renal Impairment, Anuria, and Addison's Disease. Caution is mandated in cases of Severe Hepatic Impairment due to the risk of precipitating hepatic coma. Additionally, Gynecomastia is noted as being related to the duration and dosage of therapy.

These safety domains establish the necessary boundaries for the use of this medication as defined by regulatory authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Tide Plus (Spironolactone and Torasemide) is formally documented in regulatory labeling as a medical emergency requiring immediate attention. The drug’s combined actions can lead to severe physiological manifestations defined by profound fluid and volume depletion.

Primary clinical signs of overdosage involve severe Hypotension and Hypovolemia, which may progress to Circulatory Collapse. Critical complications arise from life-threatening electrolyte disturbances, notably Hyperkalemia (dangerously high potassium) and severe Hyponatremia (low sodium). The risk of developing severe complications, including Cardiac Arrhythmias, is officially recognized. For patients with pre-existing hepatic impairment, regulatory information notes that overdose may precipitate Hepatic Coma or Encephalopathy.

Regulatory guidance explicitly states that if an overdose is known or suspected, or if symptoms such as severe dizziness, lethargy, or signs of heart rhythm changes occur, emergency medical services must be contacted immediately. Hospital monitoring is required for observation.

Management in a hospital setting is restricted to symptomatic and supportive treatment because no specific antidote is known for this combination. Official documents mandate the correction of fluid and electrolyte imbalance and close monitoring, including continuous ECG monitoring, to manage the significant risks associated with hyperkalemia.

Therapeutic Uses of Tide Plus

Tide Plus is employed primarily to address symptom patterns associated with systemic imbalance and elevated blood pressure, playing a supportive role in the long-term management of chronic diseases. It is relevant for easing symptoms related to heightened physiological activity. The medication is used for treating conditions like heart failure, resistant hypertension, and edema associated with cirrhosis. The combination may assist with easing symptoms related to volume overload, helping to address noticeable physical discomfort and strain.

Key Therapeutic Focus

This medication is commonly used across conditions presenting with systemic discomfort, such as heart failure and severe liver cirrhosis, to address fluid accumulation. It is used for managing symptoms related to fluid retention and is considered relevant for use in conditions where additional symptomatic support is needed. Brief Listing of Indications: The drug is commonly used to help with symptoms related to fluid retention (edema), ascites, and resistant high blood pressure.

“The therapy is applied to assist with symptoms related to swelling, which may help improve day-to-day comfort during symptomatic periods.”

The therapy is applied to assist with symptoms related to swelling, which may help address symptoms related to physical discomfort and can assist with the strain caused by fluid buildup. The medication contributes to easing the overall symptom load related to heightened physiological activity and supports patients during difficult episodes by easing distress related to systemic imbalance.

Quick Fact: Relief for Excess Fluid and Swelling

Eligibility and Restrictions for Use

The official eligibility profile for this fixed-dose combination is defined by strict regulatory constraints related to electrolyte balance, adrenal function, and organ status.

Category Official Regulatory Statement
Populations for whom use is contraindicated Patients with Hyperkalemia, Anuria, Addison's disease, Hepatic Coma or pre-coma, Severe Kidney Disease (creatinine clearance less than 30 mL/min), or known Hypersensitivity to the active agents or sulfonylureas.
Age-related eligibility rules Adults are the established population for use. Pediatric use is not recommended (under 12 or 18, depending on region) because safety and efficacy have not been established. Older adults require caution due to increased susceptibility to electrolyte imbalance.
Pregnancy and lactation eligibility status Pregnancy and Lactation are generally not recommended due to potential risks, requiring professional evaluation before use.

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in conditions causing high serum potassium levels and in patients with a history of Addison's disease.
  • Use is prohibited in cases of Anuria or Severe Kidney Disease and is only allowed with caution in patients with other forms of Impaired Renal or Hepatic Function.
  • Use is not established in children, and the medication is not recommended for use during pregnancy or breastfeeding.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine primarily through absolute contraindications that prevent severe complications arising from the drug's mechanism, such as exacerbating existing electrolyte imbalances. Non-eligibility is also strictly enforced for populations lacking established safety data, such as children, or during physiological states like pregnancy.

What should I know about interactions with other medicines?

The interaction profile of Tide Plus (Spironolactone and Torasemide) is officially structured around the documented risk of altering potassium balance and modifying the systemic concentration of co-administered medicines.

Contraindicated and High-Risk Combinations

Co-administration is formally restricted with Potassium Supplements (including high-potassium salt substitutes), Eplerenone, and other Potassium-Sparing Diuretics (e.g., amiloride, triamterene). This prohibition is documented due to the significant and potentially life-threatening risk of hyperkalemia (elevated blood potassium levels).

Pharmacodynamic and Functional Interactions

Combining the medication with ACE Inhibitors or ARBs is also documented to increase the risk of hyperkalemia. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as Indomethacin, are cited in regulatory documents as potentially reducing the diuretic and antihypertensive effects of the active ingredients. The use of the medication with other hypotensive agents or alcohol may lead to additive effects on blood pressure.

Metabolic and Exposure Modification

Regulators document that the Torasemide component is metabolized by CYP2C9. Co-administration with CYP2C9 Inhibitors (e.g., Fluconazole) results in officially documented increased Torasemide plasma exposure, while CYP2C9 Inducers (e.g., Rifampin) decrease exposure. Furthermore, Tide Plus reduces the renal clearance of Lithium, leading to increased Lithium plasma levels and a risk of toxicity. Spironolactone may also reduce Mitotane plasma levels.

Timing Constraints

To ensure proper absorption of the Torasemide component, substances such as Cholestyramine require a mandatory time separation of administration, as documented in regulatory labeling.

Population-Specific Notes

The official label notes that for patients with hepatic impairment/cirrhosis, the rapid alteration of fluid and electrolyte balance may precipitate hepatic coma.

Mechanism of Action

Dual Blockade of Kidney Ion Transport

This fixed-dose combination targets two distinct molecular pathways to regulate the excretion of salt and water. Torasemide acts first by inhibiting the Na^+/ K^+/ 2 Cl^- cotransporter ( NKCC2) in the loop of Henle, initiating a significant loss of sodium, chloride, and water. This targeted blockade of the primary ion-handling machinery in the kidney's concentrating segment results in a substantial reduction in circulating fluid volume. This alteration of fluid handling is the basis for the subsequent systemic changes.

️ Aldosterone Antagonism and Electrolyte Modulation

The second mechanism, driven by Spironolactone, involves competitively blocking the Mineralocorticoid Receptor ( MR) in the distal nephron. This action prevents the salt-retaining effects of aldosterone, neutralizing the body's compensatory mechanisms that would otherwise limit fluid excretion. This mechanism reduces the secretion of potassium, counteracting the increased potassium excretion driven by the first component.

Mechanistic Synergy for Systemic Fluid Modulation

The complementary actions of blocking ion transport upstream and neutralizing aldosterone signaling downstream create a synergistic effect, maximizing fluid output. This combination modulates the potassium-sodium exchange ratio. This coordinated, dual-target modulation of the fluid regulation pathway results in a reduction in systemic fluid volume and cardiac preload. This action modulates systemic fluid balance.

Dosage and Administration Information

How to Use Tide Plus: Official Administration Guidelines

This section outlines the standardized administration principles for the fixed-dose combination of Spironolactone and Torasemide (Tide Plus).

Core Administration Protocol

The medicine is designed for oral administration as a fixed-dose tablet. The standard usage pattern is once daily, typically administered in the morning to prevent increased nighttime urination. For consistent absorption, the medication may be taken with or without food, but guidance stresses the importance of consistent intake relative to meals (e.g., always taking it with food). The tablet must be swallowed whole with water and must not be crushed, chewed, or broken, which ensures the appropriate release of both active ingredients.

Dosing Schedule and Special Populations

Usage Constraint Instruction Regulatory Context
Standard Regimen Take one fixed-dose tablet once daily. The specific strength is selected by a healthcare professional. FDC Usage Principle
Missed Dose If a dose is missed, do not double the dose. The patient should skip the missed dose if the next one is due shortly, and then resume the regular schedule. Procedural Standard
Population Adjustment Dose modification is required for patients with hepatic (liver) or renal (kidney) impairment. The medicine is not recommended for use in children under 18 years of age. Safety and Efficacy Scope

This medicine is generally utilized as part of a long-term maintenance plan for chronic fluid and volume management. The specific instructions regarding timing and consistency ensure stable drug levels and adherence to the structured therapeutic protocol.

Recent Clinical Evidence

Tide Plus: Recent Clinical Evidence

Research for Chronic Heart Failure (CHF)

Research has explored the strategy of combining Spironolactone with a loop diuretic like Torasemide for managing symptoms associated with Chronic Heart Failure (CHF). Studies, including systematic reviews and controlled trials, have been used in research exploring how symptoms change over time related to fluid accumulation. Researchers monitored outcomes related to physical discomfort, such as edema, and tracked cardiovascular events like hospitalization. Findings often rely on trials of the individual component agents or similar combination diuretic strategies, which provides context for the fixed-dose combination (FDC).

Research for Resistant Hypertension

The evidence base for this combination diuretic approach in Resistant Hypertension largely relies on meta-analyses and controlled trials that studied the addition of the Spironolactone component to complex multi-drug regimens. These studies examined symptom variability by monitoring blood pressure measurements (office and ambulatory) to track patterns in how patients responded. Research highlights changes measured during the study period, but comparative evidence is lacking from dedicated large-scale RCTs specifically focused on this FDC.

Research for Volume Overload (Edema and Cirrhosis/Ascites)

The combination strategy was observed in various research settings, including Randomized Controlled Trials (RCTs), where it was used in research exploring how symptoms change over time related to fluid retention. Studies monitored outcomes related to systemic imbalance, including urine output, weight change, and the resolution of swelling (ascites). Reported outcomes often used a different loop diuretic alongside Spironolactone, providing a proxy for the Torasemide component.

Evidence Limitations and Research Gaps

A major limitation is that comparative evidence is lacking from large-scale trials that specifically tested the fixed-dose product against other standard therapies. Long-term effects are not fully established for the FDC, meaning data regarding sustained clinical outcomes are still emerging. Furthermore, dedicated research in specific patient populations, such as those with severe chronic kidney disease or older adult cohorts, remains insufficient from dedicated FDC trials, and subgroup findings are uncertain.

Key Studies & References

  1. Aldosterone antagonist combined with loop diuretic in treatment of refractory ascites: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Tide Plus (FAQ)

Q: Is a generic alternative available for Tide Plus?

Official product information notes that Tide Plus contains the active ingredients Spironolactone and Torasemide. Fixed-dose combination products containing these two active ingredients may be available from various manufacturers. These products are often identified by the generic names of the components.

Q: Can taking Tide Plus make me feel drowsy or affect my ability to drive?

Regulatory documents state that this medicine may cause dizziness or drowsiness, particularly when you first start treatment. Patients who experience these effects are generally advised to avoid driving or operating hazardous machinery until they understand how the medication affects their coordination and concentration.

Q: Is it normal to have a slight headache when starting Tide Plus?

Headache is listed as a common reported side effect of the active ingredients in official product information. This effect may occur as your body adjusts to the treatment, but any persistent or severe headache should be reviewed by a healthcare professional.

Q: Can I drink alcohol while I'm taking Tide Plus?

Official information suggests caution regarding alcohol consumption. Alcohol may combine with this medicine to produce additive effects in lowering blood pressure. This can increase the risk of dizziness or dehydration.

Q: Are there any foods I should specifically avoid while on Tide Plus?

Due to the risk of high potassium levels (hyperkalemia) caused by the Spironolactone component, the official label recommends avoiding foods that are very high in potassium or using salt substitutes that contain potassium.

Q: Is it true that Tide Plus can cause changes in weight?

The medicine is designed to remove excess salt and water from the body. Weight loss related to fluid removal is commonly observed, as this is the intended effect of the diuretic. Other specific weight changes are not consistently documented as a common side effect.

Q: How long does Tide Plus typically stay in your system after you stop taking it?

The Torasemide component is eliminated relatively quickly from the body. However, the active metabolites of Spironolactone have longer half-lives. This means the overall duration of the medicine's effect can be extended, and drug levels may not be completely eliminated for some time after stopping.

Q: Is Tide Plus safe for people with liver problems?

Official information states the medicine is contraindicated (not to be used) in patients who have hepatic coma or pre-coma. Regulatory documents note that caution is required in cases of severe liver impairment or cirrhosis, as rapid changes in fluid balance can potentially worsen liver function.

Q: Why do some people experience stomach upset with Tide Plus?

Nausea, vomiting, and diarrhea are documented adverse reactions listed in the official safety information. Stomach upset can also sometimes be an indication of a fluid or electrolyte imbalance, which is a key risk of the medicine's action.

Q: Can Tide Plus affect the results of common lab tests?

Yes, this medicine significantly changes serum electrolyte concentrations (such as potassium and sodium), which are routinely measured in laboratory tests. Spironolactone may also interfere with certain specific laboratory assays, including those used to measure cortisol and digoxin.

Q: What is the difference between the brand name and the generic version of Tide Plus?

Tide Plus is the brand name of the fixed-dose combination product. The generic version contains the active ingredients, Spironolactone and Torasemide. Generic products are required to contain the same active ingredients in the same strength and meet the same regulatory standards for quality and efficacy.

Q: Has Tide Plus been studied in people with kidney disease?

Official sources indicate the medicine is contraindicated (not recommended for use) in patients with severe kidney disease or Anuria (failure to produce urine). For patients with other forms of impaired renal function, official labeling suggests that caution and a potential dose modification are required.

Q: Is there a maximum amount of time someone should continuously take Tide Plus?

This medicine is generally prescribed as part of a long-term maintenance plan for chronic conditions. Official documents note that the risk of certain side effects, such as Gynecomastia (breast enlargement in males), is related to the duration and dosage of the therapy.

Q: Does exposure to sunlight matter while taking Tide Plus?

Yes, regulatory warnings indicate that the Torasemide component can cause increased skin sensitivity to sunlight, known as photosensitivity. While taking this medicine, patients are advised to take protective measures like using sunscreen and wearing protective clothing.

Q: Do you get withdrawal symptoms when stopping Tide Plus?

Abrupt discontinuation of the medication is generally not recommended. Official sources indicate that stopping the medicine suddenly may lead to a rapid return of fluid accumulation and elevated blood pressure, which should be managed by a healthcare provider.

Q: Is it common to feel a bit restless after starting Tide Plus?

Restlessness is documented in official safety information as a potential symptom of a fluid or electrolyte imbalance. Since this class of medication affects these balances, patients should report this or any unusual symptoms to their healthcare provider.

Q: What should I be aware of regarding the 'Plus' component of the medication?

The 'Plus' component refers to the second active ingredient, Torasemide. Torasemide is classified as a loop diuretic that acts powerfully at a different site in the kidney than Spironolactone, creating a dual-action approach to maximize fluid removal.

Q: Are mood changes a possible side effect of Tide Plus?

While side effects like confusion and drowsiness are listed in official documents, broad mood changes are not explicitly documented. However, severe electrolyte imbalances, which are a known risk of this medicine, can potentially cause changes in mental status.

Q: Can taking Tide Plus make me feel dizzy or lightheaded when standing up?

Yes, official warnings confirm that the medicine may cause hypotension (low blood pressure), including orthostatic hypotension. This may cause dizziness or lightheadedness, particularly when moving quickly from a sitting or lying position to a standing position.

Q: Are there any lifestyle changes that improve the effects of Tide Plus?

The medicine is prescribed to manage fluid retention. Its efficacy is supported by concurrent management of fluid and sodium intake. Adherence to any dietary or fluid restrictions suggested by a healthcare provider is noted in regulatory information as important to support the medicine's effects.

How should Tide Plus be stored and disposed of?

How to Store and Dispose of Tide Plus?

This section outlines the officially documented storage and disposal requirements for Tide Plus (Spironolactone and Torasemide) tablets.

Storage and Protection Rules Mandatory Requirement
Temperature Range Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).
Environmental Constraints Keep the medicine away from excessive heat, moisture, and direct sunlight. It must also be kept from freezing.
Container Integrity Store the tablets in the original container with the cap tightly closed.
Child Safety It is mandatory to keep this medication out of the sight and reach of children, ideally in a locked location.

Official Disposal Instructions

When discarding unused or expired Tide Plus, environmental guidelines prohibit flushing the medicine down the toilet or throwing it into the drain. Consult with a pharmacist or local regulatory authority for specific instructions on how to properly dispose of the product in accordance with national and local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tide Plus found in:

A-Z Index: